MedTrace Logo

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

NCT05245084 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2022-09-28

No results posted yet for this study

Summary

A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(3)

Conditions

  • Hypertension and Dyslipidemia

Interventions

DRUG

CKD-386(3)

QD, PO

DRUG

D013, D326, D337

QD, PO

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Jaewoo Kim, M.D. · Seoul, Gwanak-gu, South Korea, 08779

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2022-06-06
Completion
2022-06-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05245084 on ClinicalTrials.gov